WO2002074951A1 - Procede de construction d'un marqueur d'adnc servant a identifier un gene exprime, et procede d'analyse de l'expression d'un gene - Google Patents
Procede de construction d'un marqueur d'adnc servant a identifier un gene exprime, et procede d'analyse de l'expression d'un gene Download PDFInfo
- Publication number
- WO2002074951A1 WO2002074951A1 PCT/JP2002/002338 JP0202338W WO02074951A1 WO 2002074951 A1 WO2002074951 A1 WO 2002074951A1 JP 0202338 W JP0202338 W JP 0202338W WO 02074951 A1 WO02074951 A1 WO 02074951A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- restriction enzyme
- type
- cdna
- linker
- tag
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Definitions
- the present invention relates to a method for preparing a cDNA tag for identifying an expressed gene, the cDNA tag library, and a method for analyzing gene expression. More specifically, the present invention relates to a method for preparing a cDNA tag for identification corresponding to a specific region of an expressed gene product, raRNA, cDNA for the mRNA or a cDNA fragment thereof, and a method for analyzing gene expression using the cDNA tag. Things.
- the gene expression analysis methods include a direct method using the cDNA tag as it is and an indirect method using a ligated product of the cDNA tag.
- Each species has a unique gene expression pattern based on its unique genomic sequence, and even if the species of the organism is the same, the degree of cell differentiation, physiological conditions such as proliferation and aging, canceration, and infection It is thought to have a different gene expression pattern than the normal state due to various pathological conditions such as diseases and immune diseases. Therefore, if such gene expression patterns can be established and the gene expression patterns between cells can be compared with each other, identification of appropriate therapeutic targets, identification of candidate genes for gene therapy, tissue typing, legal Wide variety of applications of gene expression patterns, such as gene identification, localization of disease-related genes, and identification of indicator genes for diagnosis and diagnosis, will be possible.
- a serial analysis of gene expression (SAGE) method has been developed that can analyze a large number of transcripts by identifying limited regions of the transcript corresponding to the expressed gene region.
- SAGE serial analysis of gene expression
- a tag called “ditag” is prepared in which a short nucleotide sequence corresponding to each cDNA in a sample is dimerized, and the ditag is linked in a chain to form a single conjugate. It is to be cloned as a (container) and to determine the gene expression pattern by tag sequencing.
- the present invention is for identifying an expressed gene, which enables efficient analysis of a gene expression pattern unique to each species, and a unique gene expression pattern in a physiological state, developmental stage, various pathological states, etc. of a cell.
- a method for preparing a cDNA tag and a method for analyzing gene expression using the tag for identification.
- the method of the present invention requires less amount of cell samples for the gene analysis of the gene expression than conventional techniques, and is efficient and highly reliable.
- the expressed gene identification tag (Expressed Gene Identification cDNA Tag) is abbreviated as an EGI cDNA tag or EGI tag as necessary.
- the present invention provides a method of making a cDNA tag for identifying an expressed gene, comprising: providing a complementary deoxyribonucleic acid (cDNA);
- the cDNA fragment contains a recognition sequence for an ins type restriction enzyme, and a linker X that generates a recognition sequence for a second type S restriction enzyme is ligated to the junction with the cleaved end of the type ⁇ ⁇ restriction enzyme.
- X Create a cDNA fragment concatenation
- Linker X Linker X—Link the linker Y containing the recognition sequence of the 1st S-type restriction enzyme to the cleaved end of the cDNA tag with the 2nd S-type restriction enzyme, To create;
- Linker X amplifies the cDNA tag-linker Y conjugate
- the present invention relates to a method for forming a recognition sequence for a 2nd S-type restriction enzyme, which comprises a recognition sequence for an ins-type restriction enzyme, and a recognition sequence for a 2nd S-type restriction enzyme at a site where the cDNA fragment is cleaved with a type I restriction enzyme.
- a linker X capable of
- the present invention provides a gene expression analysis method characterized by contacting a cDNA tag library obtained by the method for producing a cDNA tag for expressing an expressed gene with a detection device having a nucleic acid to be detected immobilized thereon. I do.
- the present invention provides a method for analyzing an expression gene, comprising the steps of: linking the tags obtained by the method for producing a cDNA tag for identifying an expressed gene to each other; and determining the nucleotide sequence of the linked product.
- the analysis method includes determining the sequence of the ligated product, determining the sequence of each cDNA tag from the sequence, and determining the sequence and frequency of each cDNA tag from the sequence. And quantitative expression gene analysis methods.
- the present invention provides a kit for preparing a cDNA tag for identifying an expressed gene, comprising a type I restriction enzyme, a first type S restriction enzyme, a second type S restriction enzyme, and a first type S restriction enzyme.
- a linker X that generates a recognition sequence for a second S-type restriction enzyme at the junction with the cleaved end of the type I restriction enzyme, and a linker that includes a recognition sequence for the first type S-restriction enzyme
- the kit which comprises one Y.
- tags of short nucleotide sequences isolated from certain locations within a gene transcript contain enough information to identify the transcript.
- a tag of 9 bp sequence can have 4 9, that is, 262,144 types of sequences, and can identify the corresponding number of transcripts.
- the human genome encodes about 80,000-200,000 transcripts (Fields et al., Nature Genetics, 7: 345, 1994). Therefore, theoretically, if a 9 bp sequence tag can be obtained, all human gene transcripts can be identified. For lower eukaryotes and prokaryotes, the number of transcripts encoded by the genome is smaller, allowing for smaller tags.
- tags as short as 6-7 bp are sufficient to identify transcripts. Since the method of the present invention provides a single cDNA tag for identification of an expressed gene having various nucleotide lengths corresponding to each gene transcript, it is useful for analyzing gene expression patterns.
- the analysis of expressed genes can be performed by performing a single amplification process on a single short cDNA tag sandwiched between the upstream and downstream linkers, so that the bias caused by amplification and / or cloning can be obtained. Is unlikely to occur.
- the cDNA corresponding to the EGI cDNA tag sequence can be qualitatively and quantitatively measured to examine the pattern of the corresponding expression gene. That is.
- a linker (container) without or with a spacer sequence is prepared, and cloned using a vector or the like as necessary. It can be analyzed continuously and efficiently.
- the cDNA tags are independent sequences, it is easy to analyze the sequence of the ligated product, and it is also easy to isolate a single cDNA tag from the ligated product.
- the present invention and the above-described SAGE method are common in that they apply the first principle that a short nucleotide sequence tag contains a sufficient amount of information to identify a transcript.
- the SAGE method utilizes a dimerized tag called “ditag”, and a single identification cDNA tag created by the present invention, a library thereof, a single library, and the like. The difference is that a continuum consisting of cDNA tags for identification of is not created.
- FIG. 1 is a schematic diagram showing the steps (1) to (6) of one embodiment of the method for producing a cDNA tag for identifying an expressed gene according to the present invention. It is an arbitrary base selected from A, T, C or G in FIG.
- FIG. 2 is a schematic diagram showing the steps (7) to (10) of one embodiment of the method for producing a cDNA tag for identifying an expressed gene according to the present invention.
- EGI cDNA tag for identifying an expressed gene
- FIGS. 1-10 A preferred embodiment of the present invention will be described based on a method for producing a cDNA tag for identifying an expressed gene (hereinafter referred to as an EGI cDNA tag) shown in the flowcharts of FIGS.
- an EGI cDNA tag and its libraries that exhibit gene expression of a particular cell, tissue or cell extract at a particular stage of development or a particular disease state are readily obtained.
- the cDNA fragment contains a recognition sequence for an ins type restriction enzyme, and a linker X that generates a recognition sequence for a second type S restriction enzyme is ligated to the junction with the cleaved end of the type ⁇ ⁇ restriction enzyme.
- a linker Y containing a recognition sequence of the first S-type restriction enzyme is ligated to the cut end of the linker X-cDNA tag by the second S-type restriction enzyme, and the linker X-cDNA tag linker Create a Y-connection;
- a method for producing a cDNA tag for identifying an expressed gene comprising separating the obtained cDNA tag for identifying an expressed gene as necessary.
- a cDNA to be a sample In the step (1), prepare a cDNA to be a sample. Usually, first, raRNA is prepared from the test cells, and cDNA is prepared using reverse transcriptase.
- the cDNA may be either a cDNA corresponding to the full-length mRNA or a fragment thereof.
- the test cells are not limited as long as they produce mRNA having a poly A tail at the 3 'end, and include any cells such as animal cells, plant cells, and microbial cells. Animal cells, plant cells, and microbial cells infected with the virus can be used as test cells.
- analysis can be performed if 1 ⁇ g of mRNA is present. Since 1 zg of mRNA is usually obtained from 1 mg of cells, the present invention is particularly effective when handling valuable human tissue samples obtained by eddle biopsy or the like.
- raRNA separation of raRNA from test cells can be performed by a commonly used technique. For example, test cells are treated with guanidine reagent, phenol reagent, etc. to separate total RNA, and then affinity column method using poly-U-sepharose using oligo dT-cellulose ⁇ Sepharose 2B as carrier ⁇ batch method And the like to obtain mRNA.
- a first-strand cDNA (single-strand cDNA) was synthesized using oligo dT primer and reverse transcriptase, Synthesize double-stranded cDNA).
- the oligo dT primer include a solid-phase immobilized oligo dT primer, a coenzyme-labeled oligo dT primer, and the like.
- a solid-phase immobilized oligo dT primer is preferable in terms of reproducibility and the recovery rate of a target DNA fragment. .
- Oligo dT primers immobilized on latex beads, oligo dT primers immobilized on magnetic beads, and the like are used as the solid phase-immobilized oligo dT primers. Oligo d; r primers immobilized on magnetic beads are preferred.
- the cDNA in the sample is cleaved with a type II restriction enzyme to form a cDNA fragment.
- the cDNA in the c sample is a double-stranded cDNA bound to a solid-phase-immobilized oligo dT primer.
- type II restriction enzyme refers to a restriction enzyme that recognizes a predetermined recognition sequence and cuts DNA at a specific position inside or adjacent to the recognition sequence.
- a type II restriction enzyme having a recognition sequence consisting of 4, 5 or 6 ′ bases is preferable.
- Examples of the type II restriction enzyme used in the present invention include Afal, Alul, CviRI, Dpnl,
- These type II restriction enzymes include those having a recognition sequence containing all four bases ATCG, those containing only CG, and those containing only AT.
- type II restriction enzymes whose recognition sequence includes all of ATCG include Afal, Alul, CviRI, Dpnl, HpyC, HpyF44III, Rsal, Bfal, Csp6I, HpyCH4IV, Mael, Maell, TaqAlphal, Taql, TthHBSI, Xspl, There are Bspl43I, DpnII, Mbol, Ndell, Sau3AI and NIalll.
- type II restriction enzymes whose recognition sequence contains only CG include AccII, Bshl236I, BstUI, BsuRI, FnuDII, Haelll, Mvnl, Acil, BsiSI, HapII, Hin6I, HinPlI, Hpall, Mspl, SciNI, Cfol, and There is Hhal.
- type II restriction enzymes whose recognition sequence contains only AT include Msel, Trull, Tru9I, Tasl, Tsp509I, and TspEI. It is preferable to select a type II restriction enzyme in consideration of the characteristics of these recognition sequences and the characteristics of the expressed gene whose IIS type restriction enzyme is to be analyzed.
- the type II restriction enzyme is selected so as to form a cleaved end which becomes a recognition sequence for the desired type II II S restriction enzyme.
- the recognition sequence is “5′-GTAC-3 ′”, and the type 11-type pentazyme, Rsal or Rsal, which cleaves the phosphodiester bond between T and Afal may be used.
- the cDNA fragment contains a recognition sequence of the 1st S-type restriction enzyme, and a portion of the cDNA fragment which is connected to the cleavage end of the 1st-type restriction enzyme is a recognition sequence of the 2nd-S type restriction enzyme. Is ligated to create a linker X—cDNA fragment ligated product.
- a cDNA fragment containing an oligo dT primer sequence is separated from the cDNA fragment group obtained in the step (2). Separation can be performed using the label of the oligo dT primer. For example, when the oligo dT primer immobilized on latex beads is used for the preparation of the cDNA, the cDNA containing the oligo dT primer sequence immobilized on the beads is treated with a type II restriction enzyme and centrifuged. Fragments can be sedimented and separated.
- the cDNA fragment obtained here contains the poly A tail of raRNA and the cleavage end site of the type II restriction enzyme that first appears from the poly A tail toward the 5 ′ upstream side.
- Linker-X is ligated to the cDNA fragment using DNA ligase (for example, T4 DNA ligase).
- linker-1x includes a recognition sequence for an ins type restriction enzyme, and a second ⁇ S type restriction site at the junction of the cDNA fragment with the type ⁇ ⁇ restriction enzyme cleavage end.
- the recognition sequence is preferably at a position where the first IIS type restriction enzyme cuts the cDNA tag so as not to leave a spacer sequence, or at an appropriate position so as to leave a desired spacer sequence. .
- a linker X having a recognition sequence of BseRI as a recognition sequence of type II S restriction enzyme and linking to a cDNA fragment obtained when RsaJ is used as type II restriction enzyme has the following structure: There is a single-stranded DNA fragment.
- ins-type restriction enzyme refers, in principle, to an IIS-type restriction enzyme capable of recognizing a common recognition sequence on Linker X and Linker Y and forming a desired EGI cDNA tag; It also includes type I and type II restriction enzymes that exert similar functions.
- Examples of the first IIS type restriction enzyme include Mmel, Bpml, Bsgl, BspGI, Eco57I, Gsul, BsraFI, Bcefl, Fokl, Bbvl, Bsp423I, Bst71I, RleAI, Ecil, BseMII, BseRI, Hgal, Lel, There are SfaNI, Aprl, BspMI, Hphl, MboII, Mnll, Bbsl, BciVI, BbvII, Bpil, Bpll, BpuAI, and Faul.
- the first IIS type restriction enzymes whose distance from the recognition sequence to the longest end is 10 bases or more include Mmel, Bpml, Bsgl, BspGI, Eco57I, Gsul, BsmFI, Bcefl, Fokl, Bbvl, Bsp423I, There are Bst71I, RleAI, Ecil, BseMII, BseRI, and Hgal.
- the first IIS type restriction enzymes having a distance of 16 bases or more include Mmel, Bpml, Bsgl, BspGI, Eco57I, and Gsul.
- IIS restriction enzyme refers to the recognition sequence of the junction formed between linker X and the cDNA fragment in principle, and determines the appropriate position of the cDNA fragment. It contains type II restriction enzymes that cleave, and type I and type II restriction enzymes that exhibit similar functions. Cleavage of the second IIS type restriction enzyme yields a ligated product of linker X and a cDNA tag.
- Examples of the second IIS type restriction enzyme include Mmel, Bpml, Bsgl, BspGI, Eco57I, Gsul, BsmFI, Bcefl, Fokl, Bbvl, Bsp423I, Bst71I, RleAI, Ecil, BseMII, BseRI, Hgal, Lwel, SfaNI , Aprl, BspMI, Hphl, MboII, Mnll, Bbsl, BciVI, BbvII, Bpil, Bpll, BpuAI, and Faul.
- the second IIS restriction enzymes whose distance from the recognition sequence to the longest end is 10 bases or more include Mmel, Bpml, Bsgl, BspGI, Eco57I, Gsul, BsmFI, Bcefl, Fokl, Bbvl, Bsp423I, There are Bst71I, RleAI, Ecil, BseMII, BseRI, and Hgal.
- the second IIS type restriction enzymes having a distance of 16 bases or more include Mmel, Bpml, Bsgl, BspGI, Eco57I, and Gsul.
- the first IIS type restriction enzyme does not need to limit the sequence of the cleavage site.
- the combination of the second IIS type restriction enzyme is not limited.
- the type II restriction enzyme one that can form a recognition sequence for the second type II restriction enzyme in the linkage between the linker X and the cDNA fragment must be selected. For example, there is a combination of the following type II restriction enzyme and the type II IS restriction enzyme.
- the symbol * at the right end of the above table is a combination that requires a random sequence for the linker Y because the cleavage position of the positive strand is farther from the cleavage position of the complementary strand, and the number to the right of * is the number of bases. Is shown.
- the linker-X-cDNA fragment ligated product is cleaved with a second S-type restriction enzyme to prepare a linker-X-cDNA-tagged product.
- a second S-type restriction enzyme for example, when BsmFI is used as the second II S-type restriction enzyme, the enzyme is used as the recognition sequence “5′-GGGGAC-3 ′” formed in the linker X-cDNA fragment ligated product and its recognition sequence. Recognizes the double-stranded DNA consisting of complementary proteins, and cuts the position of "5'-GGGAC-3 '(10/14)".
- BsmFI is a phosphodiester bond between the 10th base and the 11th base 3 'downstream from the 3'-terminal base C of the recognition sequence "5'-GGGAC-3'", and the recognition sequence "5'- GGGAC-3 ', the complementary strand ⁇ 3'-CCCTG-5' J cleaves the phosphoryl bond between the 14th base and the 15th base 5 'upstream from the 5' base G of the 5 'end of the J Generates a DNA fragment with a truncated end with a structure c
- the linker X-cDNA fragment ligated product is cleaved with the second ⁇ S type restriction enzyme in the step (4).
- the linker-X-cDNA tag ligated product thus obtained is purified. This purification can be performed by removing the remaining cDNA fragment from which the cDNA tag has been excised, using the label of the labeled oligo dT primer, as described in step (3).
- the oligo dT primer immobilized on latex beads is In the preparation of DNA fragments, the remainder of the cDNA fragment containing the labeled oligo dT primer sequence can be sedimented and removed by centrifuging the restriction enzyme-treated solution using the sedimentation of latex beads. it can.
- the centrifuged supernatant contains the linker X-cDNA tag conjugate.
- the end of the cDNA tag of the linker X-cDNA tag conjugate is brought into a state in which a linker Y containing a recognition sequence of the first type S restriction enzyme can be bound.
- the treatment method there is a method of adding a DNA polymerase and dNTP to a solution from which the remainder of the cDNA fragment containing the labeled oligo dT primer sequence has been removed, and filling the protruding ends.
- Taq polymerase and dATP are further added, one base of adenine is added to the 3 'end.
- the above-mentioned cleaved end obtained by the treatment with the II S type restriction enzyme BsmFI has the following terminal structure by the treatment with Taq polymerase.
- the underlined part of the sequence is a newly synthesized sequence.
- a linker Y is ligated to the linker X-cDNA tag ligated product at the end of the second ⁇ S-type restriction enzyme digestion to form a linker X-cDNA tag-linker Y ligated product. create.
- linker Y is ligated to the linker X-cDNA tag ligated product which has been subjected to terminal treatment as necessary using DNA ligase (for example, T4 DNA ligase).
- DNA ligase for example, T4 DNA ligase
- linker Y refers to a linker that includes a recognition sequence for a Type II S restriction enzyme (eg, BseRI). Further, the recognition sequence is preferably located at a position where the first IIS type restriction enzyme cuts the cDNA tag so as not to leave the spacer sequence, or at an appropriate position so as to leave a desired spacer sequence. preferable.
- a linker Y linked to a DNA fragment obtained by the step (6) and having one adenyl at the 3 ′ end added thereto there is a D fragment having the following structure.
- the linker X-cDNA tag linker-amplified product is amplified.
- the ligated product obtained in the step (7) has a sequence in which the primers X and Y hybridize to the linkers X and Y, respectively, and can be easily amplified by the polymerase chain reaction (PCR).
- the PCR method may be a standard polymerase chain reaction method, for example, as described in US Pat. No. 4,683,195.
- the ligation may be amplified by clawing which incorporates it into a vector compatible with prokaryotes, or other amplification methods known to those skilled in the art.
- the amplification efficiency differs depending on the length of each type III DNA. .
- the appearance ratio of the amplified DNA fragments corresponding to each type III DNA in the obtained amplification product is as follows: It reflects the abundance ratio of each DNA fragment in the type I DNA mixture. Therefore, in the present invention, there is theoretically no effect due to the difference in amplification efficiency due to PCR, and the appearance ratio of each cDNA fragment in the obtained amplification product is different from that expressed in the test cells. It reflects the ratio of mRNA.
- the PCR can be performed under standard conditions such as time and temperature.
- the linker X-cDNA tag-linker Y to be amplified in the present invention has a short sequence length, a uniform length, and a high amplification efficiency. Therefore, it is possible to reduce the number of cycles of the anneal Z sequence extension. Also, changing the sequence of the linker changes the efficiency of the PCR, so that the desired efficiency of the anneal / sequence extension cycle can be achieved depending on the linker used.
- primer X '' as used herein is complementary to the nucleic acid strand of Linker-X and can act as a starting point for the reaction under conditions that induce the polymerase chain reaction. Possible, naturally occurring or synthesized oligonucleotide. Primer X hybridizes to a position on Linker X that can leave the recognition sequence of type II S-type restriction enzyme, and is long enough to start amplification in the presence of a polymerization agent. Must be something. The length required for primer X will depend on many factors, including temperature, pH, and ligase used.
- primer Y is complementary to the nucleic acid strand of the linker and can act as a starting point for the reaction under conditions in which the polymerase chain reaction is induced. Means a naturally occurring or synthesized oligonucleotide. It should be noted that a person skilled in the art can easily prepare the amplification primer based on the nucleotide sequence of the linker in consideration of the type II S type restriction enzyme without undue experimentation. There will be.
- the obtained amplification product is cleaved with a first USB type restriction enzyme to prepare a cDNA tag for identifying an expressed gene.
- a first USB type restriction enzyme for example, when BseRI is used as the first II S-type restriction enzyme, the enzyme recognizes the double-stranded DNA consisting of the sequence “5′-GAGGAG-3,” on linker X and its complementary chain. And cut "5, -GAGGAG-3 '(10/8)". That is, BseRI is a phosphogester bond between the 10th base and the 11th base 3 'downstream from the 3'-terminal base G of the recognition sequence "5'-GAGGAG-3'", and the recognition sequence 5'- Complementary strand of GAGGAG-3
- DNA fragment of linker X having a cleaved end having the following structure by cleaving the phosphodiester bond between the eighth base and the ninth base 5 'upstream from the base C at the 5' end of 3'-CTCCTC-5 ' Is generated.
- the first II S-type restriction enzyme BseRI is obtained from the sequence “5′-GAGGAG-3 ′” on the linker Y and its phase capture. Recognize the double-stranded DNA and cut "5, -GAGGAG-3 '(10/8)". That is, BseRI is a phosphodiester bond between the 10th base and the 11th base 3 ′ downstream from the base G at the 3 ′ end of the recognition sequence “5′-GAGGAG-3 ′ J, and the recognition sequence
- step (2) Rsel is used as a type II restriction enzyme, and in the step (3), a linker X containing a nucleotide chain consisting of the nucleotide sequence represented by SEQ ID NO: 1 is used;
- step (2) BsmFI is used as the second II S-type restriction enzyme, and in the step (2), a linker Y containing a nucleotide chain consisting of the nucleotide sequence represented by SEQ ID NO: 6 is used.
- step (9) When the method of the present invention was carried out using a cDNA library obtained from cell-derived mRNA, in step (9), the EGI cDNA tag live Rally is obtained.
- the cDNA corresponding to the EGI cDNA tag sequence can be qualitatively and quantitatively measured to examine the pattern of the corresponding expressed gene. .
- an EGI cDNA tag library corresponding to the cDNA to be detected is created in advance and prepared on a spotted detection device, and the sample of the subject, which is labeled with a different label, is brought into contact with the standard sample. Then, by comparing the relative signal intensities, a target can be selected.
- Known labels such as fluorescent labels and isotopes can be widely used.
- the EGI cDNA tag library is detected, and the pattern of the corresponding expressed gene is examined. Can be.
- the detection device that can be used in the present invention includes a microarray such as a DNA chip and a macroarray such as a dot hybridization.
- the support used for the detection device includes nylon membrane, nitrocellulose filter, glass plate, There are recon chips.
- the detection device refers to, for example, a device in which the obtained EGI cDNA tag is immobilized on a support, and the DNA, RNA, and fragments thereof to be detected are hybridized and detected.
- the mRNA is labeled so that cDNA can be detected.
- a radioisotope a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelating agent, an enzyme, or the like can be used as a label.
- the labeled cDNA to be detected is separated into single-stranded molecules, serially diluted as necessary, and, for example, an EGI cDNA tag corresponding to the gene to be detected is placed on each silicon chip grid. Contact with the held solid support.
- an EGI cDNA tag corresponding to the gene to be detected is placed on each silicon chip grid. Contact with the held solid support.
- the state of the sample cells and the like can be easily known.
- the EGI cDNA tag of an unknown gene is fixed and the pattern is recorded, it may be possible to re-analyze the gene when it is found in the future.
- the length of the EGI cDNA tag can be adjusted by the combination of the type II restriction enzyme and the second IIS type restriction enzyme, and the desired length varies depending on the type of organism for which the gene is analyzed.
- the length is preferably 6 to 25 base pairs, more preferably 10 to 25 base pairs, particularly preferably 10 to 16 base pairs.
- the obtained cDNA tag for identifying an expressed gene is separated as necessary.
- the separation can be performed using a method commonly used by those skilled in the art, for example, polyacrylamide gel electrophoresis.
- the expressed gene can be analyzed by linking EGI cDNA tags to each other and determining the nucleotide sequence of the linked product.
- the EGI cDNA tag obtained in the step (9) can be ligated using T4 ligase or the like because the 3 ′ and 5 ′ cohesive ends are complementary.
- the obtained EGI cDNA tag conjugate is analyzed by a method known to those skilled in the art, for example, by incorporating it into a vector and cloning it, or by reading the sequence using a sequencer. be able to.
- the competent protein generally contains 3 to 200 EGI cDNA tags, more preferably 3 to 80 EGI cDNA tags, and particularly preferably 16 to 40 EGI cDNA tags.
- the obtained concatenation contains the EGI cDNA tag phase according to the method of EGI cDNA tag formation. Some have no spacer sequence between them, while others have a spacer sequence.
- the EGI cDNA tag conjugate of the present invention can be cloned by a standard method for amplification by inserting it into a vector such as a plasmid phage, for example.
- the term "recombinant vector” refers to a plasmid, virus or other vehicle that has been created by insertion or integration of an EGI cDNA tag conjugate. Such vectors contain an origin of replication, a promoter, and specific genes that enable phenotypic selection of the transformed cells.
- many known growing vectors suitable for sequences can be used. Examples thereof include pUC18, its modified vectors pUC118, pUC19, its modified vectors pUC119, M13mpl8RFI, M13mpl9RFI, pBR322, pCR3.1, pBAD-T0F0 and its improved vectors, and
- host cell refers to a cell in which the vector can be propagated and the DNA can be expressed, and also the progeny of the host cell itself. Note that not all progeny are identical to the parent cell, as mutations may occur during replication.
- a known stable transfer method can be used such that the exogenous DNA is continuously maintained in the host.
- a known stable transfer method can be used such that the exogenous DNA is continuously maintained in the host.
- the accommodation main such prokaryotic cells such as E. coli, harvested after exponential growth phase and subsequently RbCl method by a known technique, from cells treated with Ca Cl 2 method, a D NA uptake capacity Combi Prepare tent cells. Transformation can also be carried out by election-portion or a conventional method.
- an EGI cDNA tag conjugate into a vector and determining the nucleotide sequence, 20 or more, 20 to 100, preferably about 20 to 3
- the sequence of about 0 EGI cDNA tags can be easily checked.
- peripheral blood monocytes were collected from peripheral blood derived from healthy humans using NycoPrepl. 077A (Nyco Med Pharma).
- the obtained peripheral blood monocytes were cultured at 37 ° C. for 3 hours in the presence or absence of lO g / ml lipopolysaccharide (LPS), and then, from each cultured cell, Isogen (manufactured by Nitsubon Gene) was used.
- LPS lipopolysaccharide
- Isogen manufactured by Nitsubon Gene
- mRNA was isolated from the total RNA by adsorption, and cDNA synthesis kit (Takara Shuzo) was used to prepare two-strand cDNA from the mRNA. .
- the resulting double-stranded cDNA was digested with a restriction enzyme Rsal (manufactured by New England Biolabs) at 37 ° C. for 2 hours, cut, and the magnet beads were collected on a wall with a magnet and collected to obtain the raRA.
- a fraction containing a cDNA fragment containing the nucleotide sequence between the poly A tail and the Rsal recognition cleavage site first appearing 5 ′ upstream from the poly A tail was obtained.
- a linker X containing a recognition sequence of the IIse type S restriction enzyme BseRI was ligated to the cDNA fragment fraction using T4 DNA ligase by the following three methods. In each case, the ligation of linker X could be suitably performed.
- Linker-X having the following structure was directly ligated to the blunt end generated by cutting with Rsal.
- linker X having the following structure was ligated to the cohesive end by treatment with T4 DNA ligase at 16 ° C. for 2 hours.
- the supernatant was subjected to T4 DNA polymerase treatment at 16 ° C for 2 hours in the presence of dATP, dCTP, dGTP and dTTP, and then Z-Taq for 30 minutes at 70 ° C in the presence of dATP. (Takara Shuzo) After treatment, the fragment was recovered and treated in the presence of dATP. The above treatment resulted in a protruding end with one A at the 3 'end, and a second linker Y having the following structure was connected to this by T4 DNA ligase treatment at 16 ° C for 2 hours.
- amplification was carried out by PCR with Taq DNA polymerase.
- PCR 96 Denaturation at 30 ° C for 30 seconds, annealing at 50 ° C for 1 minute, a total of 25 cycles of amplification at 72 ° C for 1 minute, and a final extension reaction at 72 ° C for 2 minutes. went.
- the obtained PCR product was treated with IIS type restriction enzyme BseRI (New England Biolabs). Since the cleavage site of this enzyme is located at "5'-GAGGAG-3 '(10/8)", the following structure was used to generate a DNA fragment.
- the obtained cDNA tag was ligated again with T4 ligase, and then subjected to 4.5 ° / 0 polyacrylamide electrophoresis to recover a binding fragment of 500 to 1000 bp.
- the recovered binding fragment has the following structure.
- the 5'-03, also adjacent to ⁇ 14, is a base derived from the 1 ⁇ 31 recognition sequence on 0.
- (N) 14 is 14 bases from cDNA 5'- ⁇ NNN NNNNN NN-3 '(SEQ ID NO: 19) is shown.
- the sequence of about 20 EGI cDNA tags was clarified in a single nucleotide sequencing operation.By sequencing about 500 samples, the types of mRNA expressed in cells and the number of each 10,000 sequences, which are thought to be able to be clarified, were identified.
- Tables 1 and 2 list some of the genes identified by this method. A homology search was performed on the base sequences of these EGI cDNA tags against a known database. Table 1 shows genes whose expression is increased by LPS stimulation, and Table 2 shows genes whose expression is suppressed by LPS stimulation. Gene whose expression is activated by LPS stimulation
- nucleotide sequence can be treated numerically regardless of its length. For example, when dealing with a base sequence having 14 bases, it can be specified numerically as follows.
- mini fragment ID (mf ID).
- the EGI cDNA tag library obtained in Example 1 can be detected by a detection device described below, and gene expression can be analyzed.
- Oligo DNA containing the corresponding sequence of the mf base sequence of 220597775, 69402230, 232235060, 110001478, and 196314601 is synthesized and spotted on a slide glass by a conventional method to prepare a DNA chip.
- the mRNA derived from LPS-stimulated peripheral blood monocytes (PBMC) obtained in Example 1 was labeled as type III and labeled with a fluorescent compound Cy 3-dUTP (* 1) (Amersham's Pharmacia) and labeled with LPS.
- This probe solution was mixed and hybridized with the DNA chip at 45 ° C in 6XSET [0.9 M NaCl N 10 ⁇ g / ml Yeast tRNA N 0.1% SDS, 120 mM Tris-HCl (pH 7.8)]. I do.
- CDNA prepared with reverse transcriptase was used as the type III mRNA for LPS-stimulated peripheral blood monocytes (P BMC) and mRNA for LPS unstimulated P BMC, respectively, and spotted on a membrane. Treat with C for 2 hours.
- P BMC LPS-stimulated peripheral blood monocytes
- mRNA for LPS unstimulated P BMC LPS unstimulated P BMC
- mf ID 26 18 Synthesizing oligo DN A comprising a nucleotide sequence of 49128, labels T 4 polynucleotide cinchona one peptidase in the DNA the [Y- 32 P] ATP (Amersham. Pharmacia, Inc.) using a 32 P (radioisotope) To obtain a probe solution.
- This probe solution is subjected to hybridization with the above nylon membrane at 45 ° C. in 6 ⁇ SET. After washing with a washing solution [6 XS SC, 0.1% SDS] at 52 ° C, perform autoradiography.
- the signal on the X-ray film of the cDNA derived from the mRNA of LPS-stimulated PBMC is more than twice as strong as that of the LPS-unstimulated PBMC.
- EGI cDNA tag library was prepared in the same manner as in Example 1, except that HpyCH4V was used in place of the type II restriction enzyme Rsal and RleAI was used in place of the type II restriction enzyme BsmFI.
- a linker-X-cDNA fragment ligated product is prepared by one of the following methods (1) to (3).
- the DNA is cleaved with RleAI using the restriction enzyme RleAI recognition sequence 5'-CCCACA-3 'generated by the connection of linker X, and the centrifuged supernatant is collected.
- the cleavage site for this enzyme is 5 '— CCCACA — 3' (1 2/9), so the recovered portion will contain a 12-base tag from cDNA following Linker-1X .
- the EGI cDNA tag library obtained in Example 4 can be detected by the detection device described below to analyze gene expression.
- Oligo D which corresponds to the genes corresponding to 69402230, 232235060, 110001478, and 196314601 and contains the corresponding sequence of the EGI cDNA tag obtained in Example 3, is synthesized, spotted on a slide glass by a conventional method, and DNA chip.
- PBMCs peripheral blood monocytes
- PBMCs peripheral blood monocytes
- a probe solution is obtained by fluorescently labeling the mRNA derived from PBMC not stimulated with LPS with the fluorescent compound Cy5-dUTP (* 2) (Amersham 'Pharmacia) as type II.
- This probe solution is mixed and mixed with the DNA chip in 6XSET [0.9 M NaCl, 10 / _ig / ml yeast tRNA, 0.1% SDS, 120 mM Tris-HCl (pH 7.8)] at 45 ° C for 10 minutes. Perform bridging.
- a test cDNA or a gene specifically expressed in a test cell can be accurately detected and analyzed with good reproducibility.
- differences in the function and morphology of any two cells can be clarified as differences in the expression state of genes, so that it can be widely applied to the analysis of all biological phenomena under living conditions or pathological conditions. it can. '
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002574342A JPWO2002074951A1 (ja) | 2001-03-15 | 2002-03-13 | 発現遺伝子同定用cDNAタグの作成方法、及び遺伝子発現解析方法 |
EP02705113A EP1369477A4 (en) | 2001-03-15 | 2002-03-13 | CONSTRUCTION METHOD FOR A cDNA TAG TO IDENTIFY AN EXPRESSED GENE AND METHOD FOR ANALYZING GENE EXPRESSION |
CA002455354A CA2455354A1 (en) | 2001-03-15 | 2002-03-13 | Method of constructing cdna tag for identifying expressed gene and method of analyzing gene expression |
US10/468,753 US20040142337A1 (en) | 2001-03-15 | 2002-03-13 | Method of constructing cdna tag for identifying expressed gene and method of analyzing gene expression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-73959 | 2001-03-15 | ||
JP2001073959 | 2001-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002074951A1 true WO2002074951A1 (fr) | 2002-09-26 |
Family
ID=18931310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/002338 WO2002074951A1 (fr) | 2001-03-15 | 2002-03-13 | Procede de construction d'un marqueur d'adnc servant a identifier un gene exprime, et procede d'analyse de l'expression d'un gene |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040142337A1 (ja) |
EP (1) | EP1369477A4 (ja) |
JP (1) | JPWO2002074951A1 (ja) |
CN (1) | CN1496402A (ja) |
CA (1) | CA2455354A1 (ja) |
WO (1) | WO2002074951A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004024953A1 (en) * | 2002-09-12 | 2004-03-25 | Kureha Chemical Industry Company, Limited | Method for preparation of cdna tags for identifying expressed genes and method for analysis of gene expression |
JP2006508661A (ja) * | 2002-12-04 | 2006-03-16 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 遺伝子発現の逐次分析を用いたdna分子の末端に対応する核酸タグの生成または決定方法(末端sage)。 |
JP2009067802A (ja) * | 2008-10-29 | 2009-04-02 | Susumu Sunaga | 抗腫瘍剤 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2852605B1 (fr) * | 2003-03-18 | 2012-11-30 | Commissariat Energie Atomique | Procede de preparation de fragments d'adn et ses applications |
JP3989936B2 (ja) * | 2005-04-07 | 2007-10-10 | 進 須永 | 抗腫瘍剤及び新規dnアーゼ |
EP2970958B1 (en) | 2013-03-15 | 2017-12-06 | Lineage Biosciences, Inc. | Methods of sequencing the immune repertoire |
CN108034705A (zh) * | 2018-01-15 | 2018-05-15 | 武汉爱基百客生物科技有限公司 | 一种全基因组甲基化高通量测序方法 |
KR102279846B1 (ko) * | 2019-12-26 | 2021-07-21 | 이원다이애그노믹스(주) | 이중 가닥 핵산 분자 및 이를 이용한 dna 라이브러리 내 유리 어댑터 제거 방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010363A1 (en) * | 1995-09-12 | 1997-03-20 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5695937A (en) * | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
US5658736A (en) * | 1996-01-16 | 1997-08-19 | Genetics Institute, Inc. | Oligonucleotide population preparation |
US5968784A (en) * | 1997-01-15 | 1999-10-19 | Chugai Pharmaceutical Co., Ltd. | Method for analyzing quantitative expression of genes |
-
2002
- 2002-03-13 JP JP2002574342A patent/JPWO2002074951A1/ja active Pending
- 2002-03-13 US US10/468,753 patent/US20040142337A1/en not_active Abandoned
- 2002-03-13 CN CNA028066235A patent/CN1496402A/zh active Pending
- 2002-03-13 EP EP02705113A patent/EP1369477A4/en not_active Withdrawn
- 2002-03-13 WO PCT/JP2002/002338 patent/WO2002074951A1/ja not_active Application Discontinuation
- 2002-03-13 CA CA002455354A patent/CA2455354A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010363A1 (en) * | 1995-09-12 | 1997-03-20 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
Non-Patent Citations (2)
Title |
---|
LAKEN S.J. ET AL.: "Genotyping by mass spectrometric analysis of short DNA fragments", NAT. BIOTECHNOL., vol. 16, no. 13, 1998, pages 1352 - 1356, XP002138136 * |
YAMAMOTO MIKIO: "Ikanishite shikkan ni kanrensuru idenshi o te ni ireruka? idenshi hatsugen profiling (PROGENEX) ho ni tsuite", JAPANESE JOURNAL OF UROLOGICAL SURGERY, 541TH THE JAPANESE UROLOGICAL ASSOCIATION TOKYO CHIHO KAI, vol. 14, no. 8, 15 August 2001 (2001-08-15), pages 981, ABSTRACT 0118, XP002952497 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004024953A1 (en) * | 2002-09-12 | 2004-03-25 | Kureha Chemical Industry Company, Limited | Method for preparation of cdna tags for identifying expressed genes and method for analysis of gene expression |
JP2006508661A (ja) * | 2002-12-04 | 2006-03-16 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 遺伝子発現の逐次分析を用いたdna分子の末端に対応する核酸タグの生成または決定方法(末端sage)。 |
US8158355B2 (en) | 2002-12-04 | 2012-04-17 | The Agency For Science, Technology And Research | Method to generate or determine nucleic acid tags corresponding to the terminal ends of DNA molecules using sequences analysis of gene expression (terminal SAGE) |
JP2009067802A (ja) * | 2008-10-29 | 2009-04-02 | Susumu Sunaga | 抗腫瘍剤 |
Also Published As
Publication number | Publication date |
---|---|
CN1496402A (zh) | 2004-05-12 |
JPWO2002074951A1 (ja) | 2005-05-19 |
EP1369477A4 (en) | 2004-07-14 |
US20040142337A1 (en) | 2004-07-22 |
CA2455354A1 (en) | 2002-09-26 |
EP1369477A1 (en) | 2003-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6383754B1 (en) | Binary encoded sequence tags | |
EP3068883B1 (en) | Compositions and methods for identification of a duplicate sequencing read | |
US6270966B1 (en) | Restriction display (RD-PCR) of differentially expressed mRNAs | |
NZ334426A (en) | Characterising cDNA comprising cutting sample cDNAs with a first endonuclease, sorting fragments according to the un-paired ends of the DNA, cutting with a second endonuclease then sorting the fragments | |
CN110719958B (zh) | 构建核酸文库的方法和试剂盒 | |
JP2005515792A (ja) | 核酸を操作するための方法および手段 | |
WO2009148560A2 (en) | Methods and compositions for nucleic acid sequencing | |
JPH08308598A (ja) | 遺伝子発現分析方法 | |
JPH10511002A (ja) | 遺伝子発現の逐次分析法 | |
MXPA03000575A (es) | Metodos para analisis e identificacion de genes transcritos e impresion dactilar. | |
AU2741899A (en) | Method of identifying gene transcription patterns | |
US6727068B2 (en) | Method for non-redundant library construction | |
WO2002074951A1 (fr) | Procede de construction d'un marqueur d'adnc servant a identifier un gene exprime, et procede d'analyse de l'expression d'un gene | |
WO1998049345A1 (en) | Methods and compositions for targeted dna differential display | |
Mahadeva et al. | A simple and efficient method for the isolation of differentially expressed genes | |
JP2004097158A (ja) | 発現遺伝子同定用cDNAタグの作成方法、及び該cDNAタグを用いる遺伝子発現解析方法 | |
JP2006508677A (ja) | 遺伝子発現のオリゴヌクレオチド誘導分析 | |
WO2014058355A1 (ru) | Способ количественного анализа терминальных нуклеотидов g-цепи теломерной днк человека | |
EP4048812B1 (en) | Methods for 3' overhang repair | |
Freeman | Differential Display of Gene Expression | |
Dunican et al. | Gene expression profiling of cells and tissues | |
KR20040092013A (ko) | 유전자의 발현양상 분석방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002574342 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002705113 Country of ref document: EP Ref document number: 2455354 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028066235 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002238865 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002705113 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10468753 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002705113 Country of ref document: EP |